Bone Biologics Corporation (BBLG)
NASDAQ: BBLG · IEX Real-Time Price · USD
2.130
+0.060 (2.90%)
At close: Mar 28, 2024, 3:49 PM
2.250
+0.120 (5.63%)
After-hours: Mar 28, 2024, 7:57 PM EDT

Bone Biologics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current2023202220212020201920182017201620152014 2013
Market Capitalization
22336-------
Upgrade
Market Cap Growth
--44.81%-91.15%--------
Upgrade
Enterprise Value
-1-1-430121188845
Upgrade
PE Ratio
-0.20-0.20-2.16-22.51-------
Upgrade
PB Ratio
0.640.610.545.51-------
Upgrade
P/FCF Ratio
-0.19-0.19-0.90-29.51-------
Upgrade
P/OCF Ratio
-0.19-0.19-0.90-29.51-------
Upgrade
EV/EBITDA Ratio
0.140.142.92-36.71-14.21-4.62-2.51-2.87-0.35-0.33-1.54
Upgrade
EV/EBIT Ratio
0.140.142.92-36.71-14.21-4.62-2.51-2.87-0.35-0.33-1.54
Upgrade
EV/FCF Ratio
0.130.131.21-24.07-27.46-3.47-1.96-2.26-1.11-1.12-1.68
Upgrade
Debt / Equity Ratio
-----0.86-0.95-1.05-0.98-1.05-0.89-1.97
Upgrade
Debt / EBITDA Ratio
-----14.21-4.63-2.81-3.13-0.38-0.42-2.42
Upgrade
Debt / FCF Ratio
-----27.46-3.48-2.19-2.47-1.20-1.43-2.64
Upgrade
Quick Ratio
3.643.642.9666.8100.040.100.720.410.520.71
Upgrade
Current Ratio
4.504.503.3366.8100.050.110.830.470.720.98
Upgrade
Interest Coverage
----1.00-0.83-2.51-2.60-0.59-8.89-6.41-2.15
Upgrade
Return on Equity (ROE)
-236.00%-236.00%-27.00%17.30%14.00%31.10%52.50%74.60%436.00%415.40%95.10%
Upgrade
Return on Assets (ROA)
-154.80%-154.80%-23.30%-94.70%-67220.10%-1006.80%-418.00%-482.60%-1146.30%-444.90%-226.40%
Upgrade
Return on Capital (ROIC)
-324.40%-324.40%-61.63%-16.78%41.89%446.92%-694.55%1580.99%-5111.71%2004.99%-83.49%
Upgrade
Earnings Yield
-477.87%-505.31%-46.27%-4.44%-------
Upgrade
FCF Yield
-510.29%-539.60%-111.16%-3.39%-------
Upgrade
Buyback Yield / Dilution
-452.14%-452.14%-151.84%-56.01%0.17%-45.07%-29.08%-3.46%-32.21%-90.37%-36.85%
Upgrade
Total Shareholder Return
-452.14%-452.14%-151.84%-56.01%0.17%-45.07%-29.08%-3.46%-32.21%-90.37%-36.85%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).